You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.
Multi-omics approaches can give insight into the gut microbiome and more, but there are still challenges to address, speakers at the ABRF meeting said.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
The researchers identified 240 metabolite-locus associations, including novel gene candidates for biotransformation and detoxification reactions.
In Genome Research this week: transcriptomic study of human brain development, metabolomic analysis of fruit flies, and more.
With a large set of data collected over time, Stanford researchers detected molecular markers for aging but saw considerable variation in "ageotypes."
The Long Life Family Study has enrolled 4,953 participants in 539 pedigrees in the US and Denmark that are enriched for exceptional longevity.
A proof-of-principle study suggests metabolite clusters may differ in non-small cell lung cancer patients depending on tumor type, disease stage, and overall survival trajectory.
Sciex will promote the Polly multi-omics platform in conjunction with its mass spectrometry instruments and differential ion mobility technologies.
Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.